Trials / Completed
CompletedNCT00225979
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly. The objective of this study is to assess the safety and efficacy of long-acting repeatable formulation of octreotide and to compare it to the safety and efficacy of surgery in patients with acromegaly who have not had any previous treatment for acromegaly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Octreotide LAR |
Timeline
- Start date
- 2002-11-01
- Primary completion
- 2005-03-01
- Completion
- 2005-03-01
- First posted
- 2005-09-26
- Last updated
- 2012-04-11
Source: ClinicalTrials.gov record NCT00225979. Inclusion in this directory is not an endorsement.